Q-omics provides the consensus-scored TEX12 profile across patient tissues and cancer cell-line models. TEX12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TEX12 is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, TEX12 RNA expression shows 12,048 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BLCA, and UVM as cancer lineages where TEX12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX12 survival associations across molecular data types. TEX12 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX12 RNA expression–survival associations across cancer types. High TEX12 expression shows unfavorable associations in MESO, SCLC, ACC and KIRP, but favorable associations in LUAD and LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify MESO as the clearest survival context for TEX12 RNA expression.
This table summarizes TEX12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TEX12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX12 shows lower tumor expression in BLCA, LUSC, BRCA, THCA and PAAD and higher tumor expression in CHOL. The BLCA box plot shows higher TEX12 RNA expression in normal versus tumor tissue (log2 FC = −0.231, t-test p < 0.001).
This table shows molecular features associated with TEX12 in patient tissues and cancer cell lines. In patient samples, TEX12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
